Literature DB >> 17126554

Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.

Michael J Mihm1, Deborah M Amann, Brandon L Schanbacher, Ruth A Altschuld, John Anthony Bauer, Kari R Hoyt.   

Abstract

Recent evidence suggests that mutant huntingtin protein-induced energetic perturbations contribute to neuronal dysfunction in Huntington's disease (HD). Given the ubiquitous expression of huntingtin, other cell types with high energetic burden may be at risk for HD-related dysfunction. Early-onset cardiovascular disease is the second leading cause of death in HD patients; a direct role for mutant huntingtin in this phenomenon remains unevaluated. Here we tested the hypothesis that expression of mutant huntingtin is sufficient to induce cardiac dysfunction, using a well-described transgenic model of HD (line R6/2). R6/2 mice developed cardiac dysfunction by 8 weeks of age, progressing to severe failure at 12 weeks, assessed by echocardiography. Limited evidence of cardiac remodeling (e.g. hypertrophy, fibrosis, apoptosis, beta(1) adrenergic receptor downregulation) was observed. Immunogold electron microscopy demonstrated significant elevations in nuclear and mitochondrial polyglutamine presence in the R6/2 myocyte. Significant alterations in mitochondrial ultrastructure were seen, consistent with metabolic stress. Increased cardiac lysine acetylation and protein nitration were observed and were each significantly associated with impairments in cardiac performance. These data demonstrate that mutant huntingtin expression has potent cardiotoxic effects; cardiac failure may be a significant complication of this important experimental model of HD. Investigation of the potential cardiotropic effects of mutant huntingtin in humans may be warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126554      PMCID: PMC1850107          DOI: 10.1016/j.nbd.2006.09.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  92 in total

1.  Digital imaging analysis for the study of endotoxin-induced mitochondrial ultrastructure injury.

Authors:  M S Joshi; E D Crouser; M W Julian; B L Schanbacher; J A Bauer
Journal:  Anal Cell Pathol       Date:  2000       Impact factor: 2.916

2.  High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.

Authors:  S J Tabrizi; A M Blamire; D N Manners; B Rajagopalan; P Styles; A H V Schapira; T T Warner
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

3.  Gene expression in Huntington's disease skeletal muscle: a potential biomarker.

Authors:  Andrew D Strand; Aaron K Aragaki; Dennis Shaw; Thomas Bird; Janice Holton; Christopher Turner; Stephen J Tapscott; Sarah J Tabrizi; Anthony H Schapira; Charles Kooperberg; James M Olson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

4.  Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease.

Authors:  N Brustovetsky; R LaFrance; K J Purl; T Brustovetsky; C D Keene; W C Low; J M Dubinsky
Journal:  J Neurochem       Date:  2005-06       Impact factor: 5.372

5.  Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice.

Authors:  D M Weinstein; M J Mihm; J A Bauer
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

6.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.

Authors:  R Lodi; A H Schapira; D Manners; P Styles; N W Wood; D J Taylor; T T Warner
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

7.  Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.

Authors:  Edward C Stack; James K Kubilus; Karen Smith; Kerry Cormier; Steven J Del Signore; Emmanuel Guelin; Hoon Ryu; Steven M Hersch; Robert J Ferrante
Journal:  J Comp Neurol       Date:  2005-10-03       Impact factor: 3.215

8.  Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage.

Authors:  M J Mihm; L Jing; J A Bauer
Journal:  J Cardiovasc Pharmacol       Date:  2000-08       Impact factor: 3.105

9.  Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.

Authors:  Carsten Saft; Jochen Zange; Jürgen Andrich; Klaus Müller; Katrin Lindenberg; Bernhard Landwehrmeyer; Matthias Vorgerd; Peter H Kraus; Horst Przuntek; Ludger Schöls
Journal:  Mov Disord       Date:  2005-06       Impact factor: 10.338

10.  Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin.

Authors:  Tamara Milakovic; Gail V W Johnson
Journal:  J Biol Chem       Date:  2005-06-27       Impact factor: 5.157

View more
  65 in total

Review 1.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

2.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

Review 3.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

4.  Circadian dysfunction in the Q175 model of Huntington's disease: Network analysis.

Authors:  Benjamin Smarr; Tamara Cutler; Dawn H Loh; Takashi Kudo; Dika Kuljis; Lance Kriegsfeld; Cristina A Ghiani; Christopher S Colwell
Journal:  J Neurosci Res       Date:  2019-07-29       Impact factor: 4.164

Review 5.  Proteostasis in cardiac health and disease.

Authors:  Robert H Henning; Bianca J J M Brundel
Journal:  Nat Rev Cardiol       Date:  2017-06-29       Impact factor: 32.419

6.  Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.

Authors:  A U Joshi; A E Ebert; B Haileselassie; D Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2018-12-11       Impact factor: 5.000

Review 7.  PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond.

Authors:  Taiji Tsunemi; Albert R La Spada
Journal:  Prog Neurobiol       Date:  2011-11-09       Impact factor: 11.685

Review 8.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 9.  Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

Authors:  Rodrigo A Quintanilla; Gail V W Johnson
Journal:  Brain Res Bull       Date:  2009-07-19       Impact factor: 4.077

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.